Johnson & Johnson’s bladder cancer treatment shows promise in a Phase II study; Acelyrin seeks a valuation of up to $1.5 billion in IPO; The FDA declines to approve Ascendis Pharma’s experimental hormone disorder therapy.
Sanofi, Maze strike $150M licensing deal for glycogen synthase 1 program
Bayer chairman wins reelection vote; Tempest Therapeutics touts its experimental liver cancer therapy; ABC News edits an interview with Robert F. Kennedy Jr. to exclude false claims about COVID-19 vaccines.
Weight-loss data positions Eli Lilly’s tirzepatide for 2023 obesity approval
Sangamo cuts 120 jobs, extends cash runway another year; FDA approves first pill for fecal transplants; Early findings in a gene therapy death suggest CRISPR was not the cause.
Elizabeth Holmes won’t report to prison this week amid appeal; Walmart’s leaders must face investor litigation over company’s alleged role in fueling opioid epidemic; RNA startup Orbital Therapeutics raises $270 million in Series A funding.